Med. praxi. 2012;9(1):13-19

Biological therapies in rheumatology

MUDr.Hana Ciferská1, prof.MUDr.Pavel Horák, CSc.1, MUDr.Jan Strojil2, MUDr.Martina Skácelová1, MUDr.Andrea Smržová1
1 III. interní klinika &ndash, nefrologická, revmatologická a endokrinologická FN a LF UP v Olomouci
2 Ústav farmakologie, Lékařská fakulta Univerzity Palackého v Olomouci

The introduction of biological agents in clinical practice led to prognosis improvement in very active rheumatoid and psoriatic arthritis

and ankylosing spondylitis patients, who did not respond to conventional therapy. The paper discusses the selected biological agents –

their indications, the follow up of their effects, the adverse events and pitfalls of their usage.

Keywords: biological therapy, TNFα inhibitors, rheumatic arthritis, ankylosing spondylitis, psoriatic arthritis

Published: February 13, 2012  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Ciferská H, Horák P, Strojil J, Skácelová M, Smržová A. Biological therapies in rheumatology. Med. praxi. 2012;9(1):13-19.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Cooksey R, Brophy S, Gravenor MB, et al. Frequency and characteristics of disease flares in ankylosing spondylitis Rheumatology (Oxford) 2010; 49(5): 929-932. Go to original source... Go to PubMed...
    2. Aletaha D, Smolen JS. The rheumatoid arthritis patient in the clinic: comparing more than 1,300 consecutive DMARD courses. Rheumatology (Oxford) 2002; 41(12): 1367-1374. Go to original source... Go to PubMed...
    3. Atzeni F, Turiel M, Capsoni F, et al. Autoimmunity and antiTNF-alpha agents. Autoimmun Rev. 2007; 7(1): 35-41. Go to PubMed...
    4. Kukar M, Petryna O, Efthimiou P. Biological targets in the treatment of rheumatoid arthritis: a comprehensive review of current and in-development biological disease modifying anti-rheumatic drugs. Biologics 2009; 3: 443-457. Go to original source...
    5. Olejárová M. Biologická léčba v revmatologii. Mladá Fronta 2010 ISBN 9788020422811.
    6. Young A, Dixey J, Kulinskaya E, et al. Which patients stop working because of rheumatoid arthritis? Results of five years' follow up in 732 patients from the Early RA Study (ERAS). Ann Rheum Dis. 2002; 61(4): 335-340. Go to original source... Go to PubMed...
    7. Boonen A, van der Heijde D, Landewé R, et al. Work status and productivity costs due to ankylosing spondylitis: comparison of three European countries. Ann Rheum Dis. 2002; 61(5): 429-437. Go to original source... Go to PubMed...
    8. Kvamme MK, Kristiansen IS, Lie E, Kvien TK. Identification of cutpoints for acceptable health status and important improvement in patient-reported outcomes, in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. Rheumatology (Oxford) 2008; 47(11): 1664-1670. Go to PubMed...
    9. Möller B, Aeberli D, Eggli S, et al. Class-switched B cells display response to therapeutic B-cell depletion in rheumatoid arthritis. Arthritis Res Ther. 2009; 11(3): R62. Go to original source... Go to PubMed...
    10. Cantaert T, Brouard S, Thurlings RM, et al. Alterations of the synovial T cell repertoire in anti-citrullinated protein antibody-positive rheumatoid arthritis. Arthritis Rheum 2009; 60(7): 1944-1956. Go to original source... Go to PubMed...
    11. Hueber AJ, McInnes IB. Immune regulation in psoriasis and psoriatic arthritis-recent developments. Immunol Lett. 2007, 15; 114(2): 59-65. Go to original source... Go to PubMed...
    12. Bacquet-Deschryver H, Jouen F, Quillard M, et al. Impact of three anti-TNFalpha biologics on existing and emergent autoimmunity in rheumatoid arthritis and spondylarthropathy patients J Clin Immunol 2008; 28(5): 445-455. Go to original source... Go to PubMed...
    13. Nannini C, Cantini F, Niccoli L, et al. Single-center series and systematic review of randomized controlled trials of malignancies in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis receiving anti-tumor necrosis factor alpha therapy: is there a need for more comprehensive screening procedures? Arthritis Rheum. 2009 15; 61(6): 801-812. Go to original source... Go to PubMed...
    14. de Vlam K, Lories RJ. Update in treatment options for psoriatic arthritis. Expert Rev Clin Immunol 2009; 5(6): 779-788. Go to original source... Go to PubMed...
    15. Goh L, Samanta A. A systematic MEDLINE analysis of therapeutic approaches in ankylosing spondylitis. Rheumatol Int. 2009; 29(10): 1123-1135. Go to original source... Go to PubMed...
    16. Combe B, Landewe RB, Lukas C, et al. EULAR recommendations for management of early arthritis. Ann Rheum Dis 2006; 66: 34-45. Go to original source... Go to PubMed...
    17. Šenolt L. Perspektivy biologické léčby revmatoidní artritidy - nové terapeutické cíle. Farmakoterapie 2008; 4: 645-652.
    18. Vencovský J, Tegzová D, Krofta K, Pavelka K. Doporučení České revmatologické společnosti k biologické léčbě blokádou TNF - doplněk standardních léčebných postupů u revmatoidní artritidy. Čes Revmatol 2004; 12: 14-20.
    19. Prevoo ML, van´t Hof MA, Kupper HH, et al. Modified disease activity scores that include 28 joint counts: development and validation in a prospective longitudinal study in patients with rheumatoid arthritis. Arthritis Rheum 1995; 38: 44-48. Go to original source... Go to PubMed...
    20. Bečvář R, Vencovský J, Němec P, Suchý D, Procházková L, Pavelka K. Doporučení České revmatologické společnosti pro léčbu revmatoidní artritidy. Účinnost a strategie léčby. Čes Revmatol 2007; 15: 73-90.
    21. Furst E, Breedveld FC, Kalden JR, et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2008. Ann Rheum Dis 2008; 67(Suppl 3): 2-25. Go to original source... Go to PubMed...
    22. Štolfa J. Biologická léčba psoriatické artritdiy. Remedia 2005; 15: 261-271.
    23. Ebringer A. Theoretical models to explain the association of HLA-B27 with ankylosing spondylitis. Scand J Rheumatol Suppl. 1990; 87: 151-163. Go to original source... Go to PubMed...
    24. Reveille JD, Maganti RM. Subtypes of HLA-B27: history and implications in the pathogenesis of ankylosing spondylitis. Adv Exp Med Biol. 2009; 649: 159-76. Go to original source... Go to PubMed...
    25. Pavelka K, Štolfa J, Vencovský J. Doplněk standardních léčebných postupů u ankylozující spondylitidy. Čes Revmatol 2004; 12: 20-30.
    26. Elliott MJ, Maini RN, Feldmann M, Long-Fox A, Charles P, Katsikis P, et al. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha. Arthritis Rheum 1993; 36(12): 1681-1690. Go to original source... Go to PubMed...
    27. Lamberg LA. A host of novel agents for treating psoriasis, psoriatic arthritis stir interest. JAMA 2003; 289: 2779-2783. Go to original source... Go to PubMed...
    28. van Vollenhoven RF. New and future agents in the treatment of rheumatoid arthritis. Discov Med. 2010; 9(47): 319-327. Go to PubMed...
    29. F Breedveld, P Emery, E Keystone, et al. Infliximab in active early rheumatoid arthritis Ann Rheum Dis. 2004; 63(2): 149-155. Go to original source... Go to PubMed...
    30. Smolen JS, Han C, Bala M, et al. ATTRACT Study Group. Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: a detailed subanalysis of data from the antitumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study. Arthritis Rheum. 2005; 52(4): 1020-1030. Go to original source... Go to PubMed...
    31. Kobelt G, Jönsson L, Young A, Eberhardt K. The cost-effectiveness of infliximab (Remicade) in the treatment of rheumatoid arthritis in Sweden and the United Kingdom based on the ATTRACT study. Rheumatology (Oxford). 2003; 42(2): 326-335. Go to original source... Go to PubMed...
    32. Smolen JS, Han C, van der Heijde DM, et al. Active-Controlled Study of Patients Receiving Infliximab for the Treatment of Rheumatoid Arthritis of Early Onset (ASPIRE) Study Group. Radiographic changes in rheumatoid arthritis patients attaining different disease activity states with methotrexate monotherapy and infliximab plus methotrexate: the impacts of remission and tumour necrosis factor blockade. Ann Rheum Dis. 2009; 68(6): 823-827. Go to original source... Go to PubMed...
    33. van der Heijde D, Dijkmans B, Geusens P, Sieper J, DeWoody K, Williamson P, et al. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum 2005; 52(2): 582-591. Go to original source... Go to PubMed...
    34. Antoni CE, Kavanaugh A, van der Heijde D, et al. Two-year efficacy and safety of infliximab treatment in patients with active psoriatic arthritis: findings of the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT). J Rheumatol. 2008; 35(5): 869-876. Go to PubMed...
    35. van der Bijl AE, Breedveld FC, Antoni CE, Kalden JR, et al. An open-label pilot study of the effectiveness of adalimumab in patients with rheumatoid arthritis and previous infliximab treatment: relationship to reasons for failure and anti-infliximab antibody status. Clin Rheumatol. 2008; 27(8): 1021-1028. Go to original source... Go to PubMed...
    36. Weinblatt ME, Keystone EC, Furst DE, et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum. 2003; 48(1): 35-45. Go to original source... Go to PubMed...
    37. Weinblatt ME, Keystone EC, Furst DE, et al. Long term efficacy and safety of adalimumab plus methotrexate in patients with rheumatoid arthritis: ARMADA 4 year extended study. Ann Rheum Dis. 2006; 65(6): 753-759. Go to original source... Go to PubMed...
    38. Sharp JT, Young DY, Bluhm GB, et al. How many joints in the hands and wrists should be included in a score of radiologic abnormalities used to assess rheumatoid arthritis. Arthritis Rheum 1985; 28: 1326-1335. Go to original source... Go to PubMed...
    39. Furst DE, Schiff MH, Fleischmann RM, Strand V, Birbara CA, Compagnone D, Fischkoff SA, Chartash EK. Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). J Rheumatol. 2003; 30(12): 2563-2571. Go to PubMed...
    40. Breedveld FC, Weisman MH, Kavanaugh AF, Cohen SB, Pavelka K, van Vollenhoven R, et al. The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2006; 54(1): 26-37. Go to original source... Go to PubMed...
    41. Mease PJ, Ory P, Sharp JT, Ritchlin CT, Van den Bosch F, Wellborne F, et al. Adalimumab for long-term treatment of psoriatic arthritis: 2-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT). Ann Rheum Dis 2009; 68(5): 702-709. Go to original source... Go to PubMed...
    42. Revicki DA, Luo MP, Wordsworth P, Wong RL, Chen N, Davis JC Jr. ATLAS Study Group. Adalimumab reduces pain, fatigue, and stiffness in patients with ankylosing spondylitis: results from the adalimumab trial evaluating long-term safety and efficacy for ankylosing spondylitis (ATLAS). J Rheumatol 2008; 35(7): 1346-1353. Go to PubMed...
    43. Aarden L, Ruuls SR, Wolbink G.Immunogenicity of antitumor necrosis factor antibodies-toward improved methods of anti-antibody measurement. Curr Opin Immunol. 2008; 20(4): 431-435. Go to original source... Go to PubMed...
    44. Nam JL, Winthrop KL, van Vollenhoven RF, et al. Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA. Ann Rheum Dis. 2010; 69(6): 976-986. Go to original source... Go to PubMed...
    45. Baumgartner SW, Fleischmann RM, Moreland LW, Schiff MH, Markenson J, Whitmore JB. Etanercept (Enbrel) in patients with rheumatoid arthritis with recent onset versus established disease: improvement in disability. J Rheumatol 2004; 31(8): 1532-1537. Go to PubMed...
    46. Davis JC Jr, van der Heijde DM, Braun J, et al. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis Rheum 2003; 48(11): 3230-3236. Go to original source... Go to PubMed...
    47. de Vlam K, Lories RJ. Efficacy, effectiveness and safety of etanercept in monotherapy for refractory psoriatic arthritis: a 26-week observational study. Rheumatology (Oxford) 2006; 45(3): 321-324. Go to original source... Go to PubMed...
    48. Voulgari PV. Golimumab: a new anti-TNF-alpha agent for rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. Expert Rev Clin Immunol. 2010; 6(5): 721-733. Go to original source... Go to PubMed...
    49. Keystone EC, Genovese MC, Klareskog L, et al. Golimumab, a human antibody to tumour necrosis factor {alpha} given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study. Ann Rheum Dis. 2009; 68(6): 789-796. Go to original source... Go to PubMed...
    50. Ramiro S, van Tubergen AM, Landewé RB. RAPID and FAST4WARD trials: certolizumab pegol for rheumatoid arthritis. Expert Rev Clin Immunol. 2010; 6(5): 713-720. Go to original source... Go to PubMed...
    51. Hazes JM, Taylor P, Strand V, et al. Physical function improvements and relief from fatigue and pain are associated with increased productivity at work and at home in rheumatoid arthritis patients treated with certolizumab pegol. Rheumatology (Oxford). 2010; 49(10): 1900-1910. Epub 2010 Jun 14. Go to original source... Go to PubMed...
    52. Fleischmann R, Vencovsky J, van Vollenhoven RF, et al. Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study. Ann Rheum Dis. 2009; 68(6): 805-811. Go to original source... Go to PubMed...
    53. Coiffier B, Haioun C, Ketterer N, Engert A. Rituximab (antiCD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood. 1998, 15; 92(6): 1927-1932.
    54. Heinzerling L, Dummer R, Kempf W, et al. Intralesional therapy with anti-CD20 monoclonal antibody rituximab in primary cutaneous B-cell lymphoma. Arch Dermatol. 2000; 136(3): 374-378. Go to original source... Go to PubMed...
    55. Cohen SB. Updates from B Cell Trials: Efficacy. J Rheumatol Suppl. 2006; 77: 12-7. Go to PubMed...
    56. Emery P, Fleischmann R, Filipowicz-Sosnowska A, et al. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum. 2006; 54(5): 1390-1400. Go to original source... Go to PubMed...
    57. Looney RJ. B cell-targeted therapy for rheumatoid arthritis: an update on the evidence. Drugs. 2006; 66(5): 625-639. Go to original source... Go to PubMed...
    58. Westhovens R, Luggen M, Russell A, et al. Abatacept provils durable improvements in RA disease status and a consistent safety profile through 3 years in the aim and attain trials. Reumatoplogy 2008; 47(Suppl 2): 46.
    59. Emery P, Kremer JM, Moreland R, et al. Long-term efficacy and safety of abatacept through 5 years of treatment in rheumatoid arthritis patients with an inadequate response to methotrexate. Rheumatology 2008; 47(Suppl 2): 48.
    60. Li T, Gignac M, Wells G, et al. Decreased external home help use with improved clinical status in rheumatoid arthritis: an exploratory analysis of the Abatacept in Inadequate responders to Methotrexate (AIM) trial. Clin Ther. 2008; 30(4): 734-748. Go to original source... Go to PubMed...
    61. Schiff M, Keiserman M, Codding C, et al. Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate. Ann Rheum Dis. 2008; 67(8): 1096-1103. Go to original source... Go to PubMed...
    62. Nishimoto N, Miyasaka N, Yamamoto K, et al. Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy. Mod Rheumatol. 2009; 19(1): 12-19. Go to original source... Go to PubMed...
    63. Jones G, Sebba A, Gu J, et al. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Ann Rheum Dis. 2010; 69: 88-96. Go to original source... Go to PubMed...
    64. Schiff M, Keiserman M, Codding C, Songcharoen S, et al. Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate. Ann Rheum Dis. 2008; 67(8): 1096-1103. Go to original source... Go to PubMed...
    65. Cunnane G, Madigan A, Murphy E, et al. The effects of treatment with interleukin-1 receptor antagonist on the inflamed synovial membrane in rheumatoid arthritis. Rheumatology 2001; 40: 62-69. Go to original source... Go to PubMed...
    66. Pavelka K, Forejtová S, Stolfa J, et al. Anti-TNF therapy of ankylosing spondylitis in clinical practice. Results from the Czech national registry ATTRA. Clin Exp Rheumatol. 2009; 27(6): 958-963. Go to PubMed...
    67. Vencovský J. a výbor České revmatologické společnosti. Bezpečnost biologické léčby - Doporučení České revmatologické společnosti. Čes Revmatol 2009; 17(3): 146-160.
    68. Mariette X, Matucci-Cerinic M, Pavelka K, et al. Malignancies associated with tumour necrosis factor inhibitors in registries and prospective observational studies: a systematic review and meta-analysis. Ann Rheum Dis. 2011; 70(11): 1895-1904. Go to original source... Go to PubMed...
    69. Strangfeld A, Hierse F, Rau R, et al. Risk of incident or recurrent malignancies among patients with rheumatoid arthritis exposed to biologic therapy in the German biologics register RABBIT. Arthritis Res Ther. 2010; 12(1): R5. Go to original source... Go to PubMed...
    70. Jansen TL. When rheumatology meets hepatology: are anti-TNFs safe in hepatitis B virus carriers? Arthritis Res Ther. 2010; 12(1): 103. Go to original source... Go to PubMed...

    Return to the content


    Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.